Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ADI-212 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on ADI-212, a putative chimeric antigen receptor (CAR) T-cell therapy targeting FOLH1 (PSMA) (Aug 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ADI-212 | ADI212|ADI 212 | Limited information is currently available on ADI-212, a putative chimeric antigen receptor (CAR) T-cell therapy targeting FOLH1 (PSMA) (Aug 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07793435 | Phase Ib/II | Cyclophosphamide + Fludarabine ADI-212 | A Phase 1/2 Trial of ADI-212 in mCRPC | Not yet recruiting | USA | 0 |